Printer Friendly

KABI PHARMACIA TO MARKET SUPRANE, ANAQUEST'S NEW ANESTHETIC, IN EUROPE

KABI PHARMACIA TO MARKET SUPRANE, ANAQUEST'S NEW ANESTHETIC, IN EUROPE
 MURRAY HILL, N.J., Jan. 16 /PRNewswire/ -- Anaquest, the pharmaceutical division of BOC Health Care, Inc., and Kabi Pharmacia AB, announced today that Kabi will become the sole European distributor of the new anesthetic pharmaceutical Suprane(TM) (desflurane). The current inhalation anesthetic market in Europe is in excess of $135 million (71 million pounds sterling).
 In order to meet the anticipated demand, Anaquest has begun a major $95 million (51 million pounds) expansion at its manufacturing site in Guayama, Puerto Rico.
 Suprane is a new inhalation anesthetic currently undergoing licensing review in a number of European countries. Suprane is also being reviewed by the U.S. Food and Drug Administration for approval.
 "We are very pleased to have such a fine partner as Kabi to Help develop the market for Suprane (desflurane) in Europe," said Dr. Roger G. Stoll, president and chief executive officer of BOC Health Care, Inc., parent company of Anaquest.
 Clinical trials have shown that Suprane demonstrates a number of important properties as compared with currently available inhalation anesthetic agents.
 Kabi Pharmacia will establish a dedicated anesthesia business unit to market Suprane in Europe. Kabi Pharmacia will be the sole distributor of Suprane in Austria, Belgium, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Liechtenstein, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, Turkey, and the United Kingdom.
 Kabi Pharmacia will have an exclusive right to market Suprane in each country, from the date Suprane receives licensure in that country. Kabi Pharmacia will obtain the necessary product registrations for Suprane in the Nordic countries, and possibly in other countries as well. Kabi Pharmacia also will provide sufficient numbers of Ohmeda Tech VI vaporizers, which are essential for the administration of Suprane, within its territory.
 Anaquest's Puerto Rican plant expansion is expected to be completed by the fourth quarter of 1992. The facility will continue to produce Ethrane(R) (enflurane), Forane(R) (isoflurane), and other Anaquest inhalation anesthetics.
 Anaquest, the world's leading producer of inhalational anesthetics, is a division of BOC Health Care, Inc., the billion-dollar international medical equipment and pharmaceutical business of Britain's The BOC Group plc. Kabi Pharmacia is a unit of Procordia Group, which reported consolidated worldwide sales of almost $6.2 billion in 1990.
 -0- 1/16/92
 /CONTACT: Lou Cafiero of BOC Health Care, 908-665-6940; Jan Ekberg, president, or Carl-Johan Wachtmeister, 46-18-16-30-00, both of Kabi Pharmacia; or Lars Lindegren, president of Kabi Pharmacia Parenterals, 46-8-695-8000/ CO: BOC Health Care, Inc.; Kabi Pharmacia AB ST: New Jersey IN: MTC SU:


CK-FC -- NY001 -- 0347 01/16/92 09:00 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 16, 1992
Words:433
Previous Article:IMCERA'S SECOND QUARTER EARNINGS PER SHARE FROM CONTINUING OPERATIONS INCREASES 22 PERCENT
Next Article:BURNS PHILP OF AUSTRALIA, OWNER OF FLEISCHMANN'S YEAST, ACQUIRES YEAST BUSINESS IN SPAIN
Topics:


Related Articles
CYGNUS ADDRESSES ANALYSTS, DISCUSSES COMPANY PROGRESS
ADVANCED THERAPEUTIC PRODUCTS TRADES ON NASDAQ BULLETIN BOARD; NEW ATPI STOCK QUOTATION SYSTEM
STUDIES IN THE NEW ENGLAND JOURNAL OF MEDICINE SUGGEST LEAST EXPENSIVE CLOT-DISSOLVER OFFERS SURVIVAL BENEFIT TO ELDERLY AND SAFETY ADVANTAGE
ATP ACQUIRES WORLDWIDE RIGHTS TO NEW NICOTINE INHALER TECHNOLOGY
KABI SIGNS CONSENT DECREE WITH FDA,
FDA DIRECTS KABI PHARMACIA TO CONDUCT CORRECTIONAL AD CAMPAIGN
PROCORDIA ANNOUNCES NEW HEALTH CARE ORGANIZATION IN THE U.S.
PROCORDIA SHAREHOLDERS CREATE PHARMACIA
MCNEIL CONSUMER PRODUCTS NAMED AS NEW DISTRIBUTOR OF CYGNUS' NICOTINE PATCH IN THE U.S. AND CANADA
CHIROSCIENCE AND PHARMACIA TO COLLABORATE; STRATEGIC ALLIANCE ON LEVOBUPIVACAINE

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters